Adsorption and aggregation of monoclonal antibodies at silicone oil-water interfaces
08 Jul, 2021 | Newsletters
| WATCH THIS WEBINAR NOW |
Protein aggregation is one of the major challenges in the development of protein-based drugs like monoclonal antibody (mAb) therapies. Being surface active, MAbs tend to adsorb to the surfaces of syringes, usually coated with a lubricant like silicone oil, which is an important source of aggregation.
This webinar discusses the adsorption behaviour of two monoclonal antibodies with different propensities to aggregate at these interfaces. The surface activity was studied through measurements of oil-water interfacial tension, surface mass adsorption (using Quartz Crystal Microbalance, QCM-D) and interfacial rheology. The efficacy of surfactants such as polysorbates and poloxamers, typically added to stabilise mAb formulations, was also investigated.
What you will learn: Why is aggregation a challenge in monoclonal antibody drug formulations in the biopharmaceutical industry? How does the adsorption of monoclonal antibodies to surfaces and interfaces lead to aggregation? How are surfactants, added to drug formulations, effective in mitigating aggregation?
If you have questions you would like to discuss, don’t hesitate to contact us! Please send your questions, comments and feedback to firstname.lastname@example.org
MAbs antibodies + silicone oil-water interface
This study shows a direct correlation between the adsorption of mAbs at oil-water interfaces and aggregation. Added surfactants also competitively adsorb to the oil-water interface, and thereby lower the mAb aggregation.
READ CASE STUDY
Adsorption, binding, and enzymatic action
This overview discusses biomolecular interactions and reactions that QSense QCM-D can extract. Analyse adsorption/desorption, binding, enzymatic activity, structure, structural change and fibril formation and more.
READ MORE HERE